Information Provided By: 
Fly News Breaks for July 26, 2018
ALXN
Jul 26, 2018 | 12:11 EDT
Piper Jaffray analyst Christopher Raymond said in a research note that he believes the pressure in Alexion is "more macro-driven than company specific." He noted that with a solid Q2 beat and FY18 raise, along with continued pipeline progress and increased certainty with regard to the complement inhibition franchise's revenue tail, there is much to like with this name, and he would recommend buying the name on weakness. He kept an Overweight rating and $170 price target on Alexion shares.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
